Caribou Biosciences to Present Clinical Data on Allogeneic CAR-T Therapies for Relapsed Diseases
Caribou Biosciences, Inc. is set to host a webcast on November 3, 2025, at 8:00 am ET, presenting clinical data from its allogeneic CAR-T cell therapies for relapsed or refractory diseases. The event will showcase updates on Vispacabtagene regedleucel (vispa-cel) for B-NHL and CB-011 for multiple myeloma. The webcast will commence with data from the ANTLER phase 1 trial of vispa-cel in r/r B-NHL patients. This therapy, a PD-1 knockout CAR-T cell therapy targeting CD19, aims to enhance CAR-T cell activity. Additionally, the CaMMouflage Phase 1 trial of CB-011 will be discussed, presenting initial clinical data in r/r multiple myeloma patients. CB-011 employs an immune cloaking strategy using a B2M knockout and B2M-HLA-E fusion protein to target BCMA. Caribou will also announce the anticipated design for the pivotal phase 3 trial of vispa-cel and the next steps in the clinical development of CB-011. The company, focused on transformative therapies for devastating diseases, will provide updates on its progress in the field of CRISPR genome-editing. The upcoming webcast by Caribou Biosciences, Inc. promises to shed light on the latest clinical data and trial designs for vispa-cel and CB-011, two promising allogeneic CAR-T cell therapies for r/r B-NHL and multiple myeloma, respectively. The event is set to provide valuable insights into the company's ongoing efforts to develop transformative therapies using CRISPR genome-editing.
